Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

Even with venture capital fundraising slowing down, Hatteras Venture Partners was able to close two new funds for investments in seed- and early-stage companies. We also have a recap of recent ...

Noom recently launched a microdosing program for GLP-1s. However, some are concerned about the use of compounded GLP-1s in this program, as they are not FDA-approved.

Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests ...

In today’s healthcare landscape, credibility doesn’t come from an agency logo. It comes from an idea that lands, a brand platform that manifests quickly, and results that speak for themselves.

Response Pharmaceuticals takes a new approach to weight loss with an oral small molecule designed to inhibit a protein called iMTP to reduce uptake of fats and cholesterol. While this drug’s ...

Some large health systems are experimenting with selling their internal capabilities — such as IT support, revenue cycle management and call center operations — to smaller hospitals as a new ...

Isaac Health, a startup specializing in cognitive care for Alzheimer’s dementia , raised $10.5 million in Series A funding to expand nationwide access to its platform. The company partners with ...

The 2025 Benefits Sentiment Index, a survey of 120 benefit consultants to self-insured employers, focuses on healthcare navigation, GLP-1 drug coverage and AI trends for healthcare benefits.